Anti-inflammatory reliever therapy for asthma

Brian Lipworth; Rory Chan; Chris RuiWen Kuo

doi:10.1016/j.anai.2019.10.002

Anti-inflammatory reliever therapy for asthma

Brian Lipworth (Lead / Corresponding author), Rory Chan, Chris RuiWen Kuo

Molecular and Clinical Medicine

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

101 Downloads (Pure)

Original language	English
Pages (from-to)	13-15
Number of pages	3
Journal	Annals of Allergy, Asthma and Immunology
Volume	124
Issue number	1
Early online date	11 Oct 2019
DOIs	https://doi.org/10.1016/j.anai.2019.10.002
Publication status	Published - Jan 2020

Access to Document

10.1016/j.anai.2019.10.002

Author Accepted Manuscript Accepted author manuscript, 1.22 MBLicence: CC BY-NC-ND

Cite this

@article{acdbbd003354484fbed2ceed861685db,

title = "Anti-inflammatory reliever therapy for asthma",

author = "Brian Lipworth and Rory Chan and {RuiWen Kuo}, Chris",

note = " Dr Lipworth reported receiving grants, personal fees, and nonfinancial support from Astra Zeneca (UK); grants, personal fees, and nonfinancial support from Chiesi (Italy); and other support from GSK (UK) during the conduct of the study and grants, personal fees, and nonfinancial support from Boehringer Ingelheim (Germany) and personal fees from Sanofi (France), Teva (Israel), Novartis (Switzerland), Cipla (India), Circassia (UK), Vectura (UK), Glenmark (UK), Dr Reddys (India), Lupin (USA), Genentech (USA), outside the submitted work. Dr Kuo reported receiving personal fees from Circassia (UK) and AstraZeneca (UK) outside the submitted work. No other disclosures were reported.",

year = "2020",

month = jan,

doi = "10.1016/j.anai.2019.10.002",

language = "English",

volume = "124",

pages = "13--15",

journal = "Annals of Allergy, Asthma and Immunology",

issn = "1081-1206",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Anti-inflammatory reliever therapy for asthma

AU - Lipworth, Brian

AU - Chan, Rory

AU - RuiWen Kuo, Chris

N1 - Dr Lipworth reported receiving grants, personal fees, and nonfinancial support from Astra Zeneca (UK); grants, personal fees, and nonfinancial support from Chiesi (Italy); and other support from GSK (UK) during the conduct of the study and grants, personal fees, and nonfinancial support from Boehringer Ingelheim (Germany) and personal fees from Sanofi (France), Teva (Israel), Novartis (Switzerland), Cipla (India), Circassia (UK), Vectura (UK), Glenmark (UK), Dr Reddys (India), Lupin (USA), Genentech (USA), outside the submitted work. Dr Kuo reported receiving personal fees from Circassia (UK) and AstraZeneca (UK) outside the submitted work. No other disclosures were reported.

PY - 2020/1

Y1 - 2020/1

U2 - 10.1016/j.anai.2019.10.002

DO - 10.1016/j.anai.2019.10.002

M3 - Article

C2 - 31610234

VL - 124

SP - 13

EP - 15

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 1

ER -